the new preventive treatment for babies suffering from supply difficulties

Victim of his own success. Deliveries to pharmacies of Beyfortus, a new preventive treatment for bronchiolitis in babies, will be temporarily suspended due to supply difficulties due to high demand, health authorities announced on Friday September 29. This decision concerns the 100 mg dosage of this new preventive medication, reserved for babies weighing more than 5 kg.

“In view of the number of doses of nirsevimab reserved for this dosage, the supply schedule of doses by the laboratory and in order to be able to honor orders already placed, the delivery of doses of nirsevimab 100 mg to pharmacies is temporarily interrupted”announced the Ministry of Health in a message addressed to professionals.

All orders placed by pharmacies until September 25 inclusive “will be delivered in the coming days”, specifies the General Directorate of Health. And “a second French delivery of doses of Beyfortus 100 mg is planned for the beginning of November”. On the industrial side, the Sanofi group says “to work” with its British partner AstraZeneca, “to identify solutions to meet this exceptional demand”.